Wednesday's Bio Pharma Drug Approval And Catalyst Watch List
By Scott Matusow:Yesterday after the Bell, Protalix (PLX) received approval from the FDA for its drug Elelyso, (taliglucerase alfa) which is a proprietary plant cell expressed recombinant Glucocerebrosidase enzyme for the treatment of a rare genetic disorder called Gaucher disease. Gaucher disease is estimated to affects about 6,000 people in the U.S.Shares of PLX rallied as high as $7.80, up $0.85 cents from Monday's close, and well over 1.00 from Tuesday's trading session intra-day lows. immediately after receiving the good news.On a related note, shares of iBio (IBIO) rallied as high as $1.80, up 0.30 cents from Monday's close, and up nearly $0.50 cents from its intra-day low during the trading session on Tuesday.In a full feature article I wrote on IBIO, I remarked how IBIO uses a similar technology to PLX, but focuses its platform called "iBioLaunch" more towards creating vaccines for potential pandemic and epidemic out breaks.Complete Story »
- Original article
- Login or register to post comments
